Tai Chi Intervention, Liver Disease Prevalence for People with OA | ACR Convergence
Drug Topics
NOVEMBER 21, 2024
Researchers explored the benefits of tai chi and prevalence of liver disease in patients with osteoarthritis.
Thu.Nov 21, 2024
198 
Clinical Safety Data Show Switching Between Rituximab Biosimilars Does Not Increase Adverse Events
Pharmacy Times
NOVEMBER 21, 2024
There were 2 main types of switches, including switching to rituximab subcutaneous and switching among different intravenous rituximab treatments.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
Despite Benefits, Mediterranean Diet Adherence in RA Remains Low | ACR Convergence
Drug Topics
NOVEMBER 21, 2024
The Mediterranean diet is largely considered one of the healthiest diets.
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
Pharmacy Times
NOVEMBER 21, 2024
In this episode of Public Health Matters, Christina Madison discusses pharmacist-physician collaborations with Amina Abubakar and Stephen Lewis.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Outcomes Vary When Cannabis Is Used for Pain Management in Rheumatic Disease | ACR Convergence
Drug Topics
NOVEMBER 21, 2024
Investigators evaluated the role that cannabis plays in pain management in different populations with rheumatic diseases.
Antibody Drug Conjugate Targeting CLDN1 Receives FDA Fast Track Designation
Pharmacy Times
NOVEMBER 21, 2024
ALE.P02 could provide further treatment options for advanced or metastatic anti–claudin-1+ squamous cancers.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
Usage of AI With PET/CT Images Could Detect Impacts of Immunotherapy in Lung Cancer
Pharmacy Times
NOVEMBER 21, 2024
The risk of developing interstitial lung disease after immunotherapy was 6.5 times higher in individuals with high inflammation.
Expiration of hospital-at-home, telehealth policies threatens nonprofit hospitals' recovery: Fitch
Fierce Healthcare
NOVEMBER 21, 2024
Not-for-profit hospital and health systems are slowly recovering from their worst year financially in 2022. | If federal lawmakers don't act to extend the Acute Hospital Care at Home program, which expires at the end of this year, it could dampen not-for-profit hospitals' nascent financial recovery, according to a new report from Fitch Ratings.
FDA Accepts sNDA for Darolutamide With ADT for Patients With mHSPC
Pharmacy Times
NOVEMBER 21, 2024
The supplemental new drug application (sNDA) is based on results from a phase 3 trial that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Sweeping nonprofit House bill passes, healthcare groups turn attention to Senate
Fierce Healthcare
NOVEMBER 21, 2024
Legislation that gives a president wide-reaching power to financially harm any nonprofit an administration deems as terrorist supporting passed out of the House of Representatives Nov. 21. | H.R. 9495 passed in the House on Thursday. If signed into law, a president would be able to take a nonprofit's tax-exempt status away without due process, critics say.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Intravenous Injections of Zanidatamab-Hrii Receives FDA Accelerated Approval for IHC+ BTC
Pharmacy Times
NOVEMBER 21, 2024
The indication is for adults with previously treated unresectable or metastatic HER2+ (IHC+) biliary tract cancer (BTC) as detected by an FDA-approved test.
Roche's Vabysmo shows potential to treat eye disorder common in Asia
Fierce Pharma
NOVEMBER 21, 2024
Few pharmaceutical products have taken the market by storm like Roche’s Vabysmo. | Interim results from a late-stage trial of Roche's Vabysmo on Asian patients with polypoidal choroidal vasculopathy suggest that the injected treatment is effective. After 16 weeks, patients showed vision improvement which was equivalent to reading roughly one and a half more lines on an eye chart.
Higher Composite Dietary Antioxidant Index Reduces Risk of Diabetes for Women
Pharmacy Times
NOVEMBER 21, 2024
Investigators also established a negative association with higher vitamin C intake and diabetes prevalence.
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
PharmaVoice
NOVEMBER 21, 2024
A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Novel IVIG Formulation KIG10 Is Effective, Well Tolerated in Adults With Primary Immunodeficiency
Pharmacy Times
NOVEMBER 21, 2024
No acute serious bacterial infections were observed in a trial of patients with the debilitating immune disorder, a strong mark of safety and tolerability.
Sotagliflozin’s Effect on BP Remains in T2D Regardless of Kidney Function | AHA 2024
Drug Topics
NOVEMBER 21, 2024
Research presented at American Heart Association’s 2024 Scientific Sessions examined the SGLT inhibitor’s effect on systolic blood pressure.
Rusfertide Reduces Phlebotomy Need, Improves Symptom Control in Polycythemia Vera
Pharmacy Times
NOVEMBER 21, 2024
Rusfertide may sustain hematocrit levels in patients with polycythemia vera.
Versant enters obesity with new startup
STAT
NOVEMBER 21, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hullo! Today, some squiddy drug delivery, a leukemia deal between Kura Oncology and Kyowa Kiri, and a new GLP-1 startup from Versant Ventures.
5 Reasons to Upgrade Your Pharmacy Management Software
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Advancing Compounding Standards: Insights From the USP Compounding Implementation Workshop
Pharmacy Times
NOVEMBER 21, 2024
The workshop addressed trends, initiatives, and regulations for quality compounding.
From promise to reality: Unlocking the true business potential of genomic medicine
pharmaphorum
NOVEMBER 21, 2024
Explore how investing in genomic medicine can unlock the true business potential in the manufacturing and therapeutic areas. Understand the promise and reality of this cutting-edge field.
After youth vaping surge, the U.K. moves to ban disposable e-cigarettes
STAT
NOVEMBER 21, 2024
LONDON — The stacks of brightly colored disposable e-cigarettes, touting flavors like cotton candy ice and greengrape melon and often looming over the not-dissimilar-looking candy displays, have become a commonplace sight in convenience stores in both the U.S. and the U.K. But here, they’re on their way out.
Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn
pharmaphorum
NOVEMBER 21, 2024
Novartis buys gene therapy specialist Kate Therapeutics for $1.
McKinsey nears $600m settlement with US government over role in opioid crisis
The Guardian - Pharmaceutical Industry
NOVEMBER 21, 2024
Consultancy firm accused of helping opioid makers boost sales, which allegedly contributed to deadly epidemic McKinsey is in the final stages of negotiating a deferred prosecution agreement to resolve a US criminal investigation into the consulting firm’s work helping opioid manufacturers boost sales that allegedly contributed to a deadly addiction epidemic , people familiar with the matter said.
Solution Spotlight: Within3
pharmaphorum
NOVEMBER 21, 2024
Discover how Within3's community-driven platform helps businesses gather and utilise data effectively. Explore our solution spotlight for insights into their innovative approach.
FDA chief: AI adoption driven by financial reasons, not patient benefits
STAT
NOVEMBER 21, 2024
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Robert Califf: Clinical care should drive AI adoption It’s day two of the FDA’s advisory committee meeting on regulating generative artificial intelligence tools.
Examining Impact of COVID-19 Diagnosis Timing on AF Progression | AHA 2024
Drug Topics
NOVEMBER 21, 2024
“[O]ur data do not support the hypothesis that early COVID resulted in more significant structural or electrical cardiac remodeling that would increase the likelihood of atrial fibrillation progression,” the authors said.
Kura Oncology partners Kyowa Kirin to advance AML treatment
Pharmaceutical Technology
NOVEMBER 21, 2024
Kura has partnered Kyowa Kirin in a strategic global collaboration for developing and commercialising oral ziftomenib to treat AML
Q&A: Chain Pharmacist Shares Keys to Success in Retail Settings
Drug Topics
NOVEMBER 21, 2024
James Rider, PharmD, shared reflections on his experiences as a pharmacy manager at CVS.
Famotidine vs. pantoprazole: Comparing uses, effectiveness, costs, and more
The Checkup by Singlecare
NOVEMBER 21, 2024
Famotidine and pantoprazole are medications commonly used to treat heartburn as well as other digestive problems, such as stomach ulcers, duodenal ulcers and the damage and inflammation of the esophagus (erosive esophagitis) caused by gastroesophageal reflux disease ( GERD ). While both drugs decrease acid production in the stomach, they differ in how they work, for what conditions they are best suited, their side effect profiles, and their availability (over-the-counter vs. prescription-only).
Eisai debuts biliary tract cancer drug in Japan
pharmaphorum
NOVEMBER 21, 2024
Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug.
Modernising drug delivery through gel-based technology
European Pharmaceutical Review
NOVEMBER 21, 2024
Accessibility, as well as optimised nutrient and medicine release, are the driving forces behind modernising drug delivery. With millions around the world struggling with dysphagia and other conditions that affect their ability to take pills and other medications, innovative delivery methods with gel-based platforms are necessary to promote greater accessibility and medication adherence.
Amoxicillin for cough and cold symptoms: What experts say
The Checkup by Singlecare
NOVEMBER 21, 2024
Amoxicillin is a generic antibiotic that can treat many infections caused by bacteria, such as pneumonia, bacterial bronchitis, urinary tract infections, and ear infections. Like other antibiotics, amoxicillin is not effective for treating viral infections like colds and the flu. But since coughing can be a symptom of various bacterial infections, such as bacterial bronchitis and pneumonia, you may wonder whether amoxicillin can help shorten the duration and severity of your cough.
Novartis raises mid-term sales outlook on pipeline promise
pharmaphorum
NOVEMBER 21, 2024
Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets
Let's personalize your content